FibroBiologics, Inc.(FBLG)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
FBLG Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for FibroBiologics, Inc. (FBLG), a Healthcare sector company. FBLG is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), FibroBiologics, Inc. reports net income of $-4.1M, free cash flow of $-3.3M. Top institutional holders of FBLG by reported 13-F value include Cascade Financial Partners, Fund Evaluation Group, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. FBLG trades on the Nasdaq exchange and files with the SEC under CIK 1958777. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FBLG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for FibroBiologics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-4.1M
Free Cash Flow
Q2 2026
$-3.3M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-67.1% YoYOperating Income
-21.2% YoYEPS (Diluted)
-23.5% YoYTotal Assets
-41.5% YoYTotal Debt
Op. Cash Flow
-37.8% YoYFree Cash Flow
-37.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Income | $-18.6M -67.1% | $-11.2M +32.3% | $-16.5M -221.9% | $-5.1M | — |
| Operating Income | $-16.6M -21.2% | $-13.7M -54.5% | $-8.9M -99.0% | $-4.5M | — |
| EPS (Diluted) | $-0.42 -23.5% | $-0.34 +50.0% | $-0.68 -277.8% | $-0.18 | — |
| Total Assets | $9.6M -41.5% | $16.4M +39.1% | $11.8M +145.0% | $4.8M | — |
| Total Debt | — | — | — | $60.0K | — |
| Operating Cash Flow | $-16.4M -37.8% | $-11.9M -85.9% | $-6.4M -57.4% | $-4.1M | — |
| Free Cash Flow | $-16.7M -37.8% | $-12.1M -75.2% | $-6.9M | — | — |
Get alerted when FBLG's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for FibroBiologics, Inc. including:
Top Institutional Holders of FBLG
Cascade Financial Partners, LLC
$103.1K108,828 shFund Evaluation Group, LLC
$49.1K51,794 shGEODE CAPITAL MANAGEMENT, LLC
$28.7K30,299 shVANGUARD CAPITAL MANAGEMENT LLC
$26.3K27,769 shQube Research & Technologies Ltd
$23.0K24,313 shBlackRock, Inc.
$17.3K18,238 shBARCLAYS PLC
$6.9K7,243 shVANGUARD FIDUCIARY TRUST CO
$6.0K6,380 shTower Research Capital LLC (TRC)
$4.5K4,728 shOSAIC HOLDINGS, INC.
$2.3K2,404 sh
| Fund | Value | Shares |
|---|---|---|
| Cascade Financial Partners, LLC | $103.1K | 108,828 |
| Fund Evaluation Group, LLC | $49.1K | 51,794 |
| GEODE CAPITAL MANAGEMENT, LLC | $28.7K | 30,299 |
| VANGUARD CAPITAL MANAGEMENT LLC | $26.3K | 27,769 |
| Qube Research & Technologies Ltd | $23.0K | 24,313 |
| BlackRock, Inc. | $17.3K | 18,238 |
| BARCLAYS PLC | $6.9K | 7,243 |
| VANGUARD FIDUCIARY TRUST CO | $6.0K | 6,380 |
| Tower Research Capital LLC (TRC) | $4.5K | 4,728 |
| OSAIC HOLDINGS, INC. | $2.3K | 2,404 |
More Healthcare Companies
View all Healthcare →Put FBLG on your watchlist
Track score changes the day FibroBiologics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is FBLG a good stock to buy?
13F Pro's AI-powered analysis of FibroBiologics, Inc. (FBLG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FBLG are available on the FBLG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. FBLG is classified as a small company.
Which hedge funds own FBLG?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FBLG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of FibroBiologics, Inc.'s investment landscape.